For harm? Or lack of efficacy? (I agree they should collect data. We should always have more data. It’s just that this seems like an edde case they put the guidelines down for, not a policy as implied by the article).
-
-
Much of the 2021 supply of the very high efficacy two-dose vaccines has been purchased by wealthy countries. So it’s either increase supply or find other combinations that work as well (I don’t know if the latter is likely or possible hence the questions).
-
This is key, both in terms of fairness and global outcomes, but also I would argue for minimising the chance of vaccine escape arising.
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.